Robert Chrzanowski, MD
Allergy & Immunology · Columbus, GANPI 1982785895
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,364 of the $115,117 with a category attached, or 75.9%. 36 manufacturers reported payments, led by GSK at 50.8% of the total. 2025 is the largest year on record at $43,017, 9.9 times the $4,341 reported in 2019. Among allergy & immunology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 598 payments — averaging $192.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$58K
- Regeneron Healthcare Solutions, Inc.$39K
- Genentech USA, Inc.$5K
- Sanofi$4K
- AstraZeneca$3K
- Biocryst Pharmaceuticals, Inc.$1K
- plus $4K from 30 others
Across 523 payments — averaging $1579.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$291K
- Regeneron$149K
- LEO Pharma AS$86K
- Novartis$71K
- GSK$63K
- Amgen$59K
- plus $106K from 4 others
What the payments were for
- Consulting fees$7,6877%
- Speaking & faculty fees$87,36476%
- Travel & lodging$6,0675%
- Food & beverage$13,75812%
- Education$2410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 142 | $58,436 |
| Regeneron Healthcare Solutions, Inc. | 78 | $39,336 |
| Genentech USA, Inc. | 30 | $5,334 |
| Sanofi | 38 | $3,580 |
| AstraZeneca | 120 | $3,097 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $484 |
| CSL Behring | 17 | $362 |
| AbbVie | 14 | $361 |
| Biocryst US Sales Co., LLC | 14 | $331 |
| Novartis | 19 | $321 |
| Amgen(2 entities) | 17 | $310 |
| Pfizer | 17 | $303 |
| Kaleo, Inc. | 13 | $252 |
| Grifols USA, LLC | 8 | $161 |
| Lilly USA, LLC | 4 | $158 |
| Optinose US, Inc. | 8 | $139 |
| ADMA Biomanufacturing LLC | 1 | $127 |
| Shire North American Group Inc | 7 | $109 |
| Incyte Corporation | 2 | $108 |
| Galderma Laboratories, L.p. | 2 | $98 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Teva Pharmaceuticals USA, Inc. | 6 | $84 |
| Pharming Healthcare, Inc. | 3 | $64 |
| Octapharma USA, Inc. | 2 | $62 |
| Alk-abello, Inc | 3 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $40 |
| Phadia US Inc. | 2 | $38 |
| Verona Pharma, Inc. | 1 | $29 |
| Cycle Pharmaceuticals Inc | 1 | $22 |
| Dermavant Sciences, Inc. | 1 | $20 |
| LEO Pharma Inc. | 1 | $18 |
| Merck | 1 | $18 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Genentech, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,117 in reported general payments places this provider in the 90th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 45 | $175,187 |
| Dupixent SyringeDupilumab | 33 | $133,586 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $98,895 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $89,943 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $41,467 |
| XolairOmalizumab | 13 | $33,056 |
| Spiriva RespimatTiotropium Bromide | 46 | $31,236 |
| Advair HfaFluticasone Propion/Salmeterol | 77 | $29,619 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $26,776 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $17,754 |
| Epinephrine | 63 | $13,263 |
| DuleraMometasone/Formoterol | 32 | $10,454 |
| Arnuity ElliptaFluticasone Furoate | 38 | $8,718 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 66 | $8,635 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $7,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $58,436 | $141,796229 claims |
| Grifols USA, LLCGamunex-C | $161 | $89,94313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,097 | $59,221113 claims |
| Genentech, Inc.Xolair | $9 | $33,05613 claims |
| Boehringer IngelheimSpiriva Respimat | $17 | $31,23646 claims |
| MerckDulera | $18 | $10,45432 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Columbus
- Robert CartwrightColumbus$169K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Belinda GrahamSmyrna$94K
- Lily HwangRoswell$88K
- Paul RabinowitzAtlanta$57K
- Ronald BeebeGainesville$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.